A federal court in Massachusetts has granted Pfizer and BioNTech’s motion to put on hold Moderna’s lawsuit over alleged ...
Think it's time for a booster? Moderna says its newest COVID vaccine is showing signs of a stronger immune response against the virus than the current shot being offered and a longer shelf-life.
Moderna stock falls 2.32% due to patent infringement suit. However, some investors see this as an opportunity to enter or average out. Golden Cross formation also offers hope for future growth.
In a press release issued in Denmark by the Danish Medicines Agency, media have been informed that a side effect of taking Moderna's COVID vaccine, also known as Spikevax, may result in chronic hives.
Shares of Moderna (MRNA) are moving up on Tuesday afternoon after the company released positive data for its individualized cancer vaccine tested in combination with Merck's Keytruda (MRK).
Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter. US biotech Moderna has put plans to build a vaccine plant in Kenya on hold, in a sign that moves to invest ...
Five years from now, Moderna could be synonymous with personalised cancer vaccines, not Covid-19. Chief executive Stéphane Bancel talks with Scottish Mortgage manager Tom Slater about what can ...
, opens new tab said on Thursday it had paused its plans to build a vaccine manufacturing facility in Kenya, following a post-pandemic decline in demand for COVID-19 vaccines. The move is in line ...
CAMBRIDGE, MA / ACCESSWIRE / March 26, 2024 / Moderna, Inc. (NASDAQ:MRNA) today announced that mRNA-1283, the Company's next-generation COVID-19 vaccine, has successfully met the primary endpoints ...
Moderna said on Thursday it had paused its plans to build a vaccine manufacturing facility in Kenya, following a post-pandemic decline in demand for Covid-19 vaccines. Moderna said on Thursday it ...
In the U.S., for every 100,000 people 23 people are diagnosed with melanoma each year and two people die from it. Texas Oncology is hoping to enroll 10 to 15 patients in the melanoma vaccine trial.